Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00909
|
|||||
| Drug Name |
Ondansetron
|
|||||
| Synonyms |
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; Apo-ondansetron; DESMETHYLONDANSETRON; GR 38032; GR 38032X; GR-38032F; GR38032F; Novo-ondansetron; Ondansetron (JAN/USP/INN); Ondansetron (Zofran); Ondansetron [USAN:INN:BAN]; Ondansetron, (+,-)-Isomer; PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran; Zofran (TN); Zofran ODT; Zofran ODT (TN); Zophren; Zudan
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Nausea and vomiting associated with chemotherapy [ICD11: MD90] | Approved | [1] | |||
| Therapeutic Class |
Antiemetics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H19N3O
|
|||||
| Canonical SMILES |
CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
|
|||||
| InChI |
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
|
|||||
| InChIKey |
FELGMEQIXOGIFQ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 99614-02-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 293.4 | Topological Polar Surface Area | 39.8 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
2.3
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:7773
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ondansetron was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.